1. Home
  2. BXC vs LYEL Comparison

BXC vs LYEL Comparison

Compare BXC & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bluelinx Holdings Inc.

BXC

Bluelinx Holdings Inc.

HOLD

Current Price

$48.80

Market Cap

410.5M

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$17.35

Market Cap

401.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BXC
LYEL
Founded
2004
2018
Country
United States
United States
Employees
1700
N/A
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
410.5M
401.8M
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
BXC
LYEL
Price
$48.80
$17.35
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$71.50
$30.60
AVG Volume (30 Days)
118.0K
51.8K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$36,000.00
Revenue This Year
$5.04
N/A
Revenue Next Year
$5.09
$8,712.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$44.78
$0.40
52 Week High
$88.30
$45.00

Technical Indicators

Market Signals
Indicator
BXC
LYEL
Relative Strength Index (RSI) 44.00 36.48
Support Level $45.39 $17.34
Resistance Level $64.10 $19.02
Average True Range (ATR) 4.03 1.22
MACD -0.20 -0.21
Stochastic Oscillator 16.03 34.78

Price Performance

Historical Comparison
BXC
LYEL

About BXC Bluelinx Holdings Inc.

BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh, and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: